HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters

Some studies do not list a clear city. Always confirm the location with the study team.

Some visits may still be in person. Participation depends on the study’s location and eligibility requirements.

4317studies shown
Showing 109-120 of 4,317
Drug study icon
RecruitingNCT07230652

Safety and Tolerability of LY03020

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Dose- Ascending Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of LPM787000048 Maleate Extended-Release Tablets (LY03020) in Chinese Adult Healthy Subjects and/or Subjects With Stable Schizophrenia

In Beijing
SchizophreniaMedication studyAges 18–60
Countries
China
Sponsor
Luye Pharma Group Ltd.
Drug study icon
RecruitingNCT05995782

FB418 or placebo: safety of single and repeated doses in healthy adults and older adults

About this title

A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418

Read the official source — NCT05995782
Official study title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD and MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral FB418 in Healthy Adult Subjects and Healthy Elderly Subjects

In Seoul
SchizophreniaMedication studyAges 19+
Countries
South Korea
Sponsor
1ST Biotherapeutics, Inc.
Drug study icon
RecruitingNCT07115329

Zelquistinel or placebo for depression symptoms

About this title

A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Read the official source — NCT07115329
Official study title

Phase 2, Multicenter, Randomized, Double-Blind Evaluation of the Efficacy and Safety of Oral GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Multiple locations, including Phoenix
DepressionMedication studyAges 18–64
Countries
United States
Sponsor
Syndeio Biosciences, Inc
Drug study icon
RecruitingNCT07478744

Safety study of SYT-510 in anxiety

What is this study about?

This study evaluates the safety and effectiveness of SYT-510 for people with anxiety.

In London
AnxietyMedication studyAges 18–55
Countries
United Kingdom
Sponsor
Synendos Therapeutics AG
Drug study icon
RecruitingACTRN12624000449538

PEX010 for Adjustment disorder

Official study title

A Phase 2b double-blind, randomized, low-dose comparator-controlled clinical trial to assess the efficacy and safety of PEX010 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to incurable cancer diagnosis

In Australia
Adjustment disorderInterventional studyAges 18–80
Countries
Australia
Sponsor
Psyence Australia Pty Ltd
Drug study icon
RecruitingNCT07592689

Study of DT120 for Major Depressive Disorder (Ascend)

What is this study about?

Researchers are comparing DT120, placebo and a simulated comparison procedure to find out how the approaches affect depression symptoms in adults with depression.

Multiple locations, including Little Rock
DepressionMedication studyAges 18–74
Countries
United States
Sponsor
Definium Therapeutics US, Inc.
Other study type icon
RecruitingACTRN12620000640909

A phase II, open label non-study of the safety and efficacy of the CovidCare app to support self-monitoring for COVID-19 symptoms in self-isolation and to determine the impacts on mental health

Official study title

A phase II, open label non-randomised clinical trial of the safety and efficacy of the CovidCare app to support self-monitoring for COVID-19 symptoms in self-isolation and to determine the impacts on mental health

In Australia
Mental healthInterventional studyAges 18+
Countries
Australia
Sponsor
University of Melbourne

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.